
|Videos|February 1, 2017
Cobimetinib Plus Paclitaxel in TNBC
Adam M. Brufsky, MD, PhD, discusses combining cobimetinib and paclitaxel as a first-line treatment in patients with advanced triple-negative breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
2
Advanced Renal Cell Carcinoma: Tailoring Second-Line Therapy After Prior Immunotherapy
3
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC
4
Teclistamab/Talquetamab Reduces Risk of Progression by 89% in R/R Multiple Myeloma
5































